© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ethionamide traces back to the frenzied search for new therapies during the mid-twentieth century, a time when tuberculosis took many lives and doctors watched antibiotics lose their punch to resistant germs. Discovered in the 1950s, its introduction followed years of research into compounds that could outmaneuver Mycobacterium tuberculosis. Interest in ethionamide rose quickly since it hit hard against strains already outsmarting isoniazid. Early adoption wasn’t smooth. Many patients dreaded the stomach cramps and odd metallic taste, but scientists, working through fast trials and persistent dosing adjustments, stuck to their mission. Public health agencies, spurred by surging multidrug-resistant (MDR) TB, gave it a spot in treatment arsenals where the need was greatest. Over decades, its use spread from specialized hospital wards to clinics in countries facing TB epidemics.
Ethionamide wears several hats in medicine. Most know it as a second-line antitubercular drug, reserved for people fighting infections resistant to first-line therapies. Pharmaceutical companies craft it into coated tablets, scored and sized for easy dosing adjustments, since sticking to a schedule is tough for patients already coping with side effects. The drug rarely gets the spotlight but plays a crucial supporting role where hope runs low. Its role in TB care reflects a stubborn medical reality: some of the oldest threats still require tailored approaches, especially for persistent cases that defy standard drugs.
This compound shows up as a pale yellow crystalline powder, sometimes appearing slightly greenish under certain storage conditions. It carries a distinctive odor, odd to the unfamiliar, but well known to workers who handle it daily. The molecular structure, C8H10N2S, gives ethionamide a modest weight and poor water solubility, nudging formulators to consider various excipients for tablet stability. Its melting point lands around 162-164°C, which reduces the risk of unwanted degradation during tablet production. Not overly volatile or combustible, it still needs careful control in manufacturing suites, especially to avoid cross-contamination.
Drug manufacturers base specifications on pharmacopeial monographs, setting purity thresholds typically above 98%. Impurity profiles draw on validated analytical techniques, including HPLC and mass spectrometry, so pharmacists have confidence in the product’s quality. Tablets often come labeled with batch numbers, bar codes, and dosing guides stringently regulated by global and local agencies such as WHO or the FDA. Storage guidance emphasizes dry, cool conditions away from sunlight—a lesson learned from earlier eras when inconsistent quality led to treatment failures. Leaflets outline dosing protocols and flag up common side effects, such as gastrointestinal upset and hepatitis risk, driving home the need for close doctor-patient partnerships.
Labs usually synthesize ethionamide by reacting 2-ethyl-4-aminopyridine with carbon disulfide, then cyclizing to yield the thioamide group. Chemists refine the process for yield, purity, and waste reduction, recognizing regulatory pressures around environmental discharge and batch traceability. Advances in green chemistry have nudged production plants to swap hazardous solvents for safer alternatives, and recycling byproducts wherever possible. While the route seems established, periodic tweaks adjust for cost and improvements in downstream processing, especially in regions where raw materials may differ in quality or availability.
Ethionamide does not lend itself well to sweeping structural changes since the thioamide core drives its biological activity. Some researchers tinker with the side chains, aiming to trim side effects, although too much modification often knocks out the antitubercular action. In the body, enzymes convert ethionamide into active forms that slam into mycolic acid synthesis, blocking bacterial cell wall construction. This stepwise activity underscores the challenge of repurposing ethionamide for other diseases: change the molecule too much and it loses its edge. Still, those combing chemical libraries for tweaks sometimes find analogues with improved metabolic profiles or reduced toxicity, but few have reached clinical shelves.
Across the world, packages bear names like Trecator, Trecator-SC, and Ethinamide, handy for doctors navigating formularies. Synonyms found in research articles include 2-ethylpyridine-4-carbothioamide and N,N'-diethylthioisonicotinamide, among other variations. These names, mixing IUPAC precision with brand familiarity, reflect the global nature of TB care. Some health workers know only the brand their clinic stocks, while regulatory paperwork sticks to the generic, creating confusion when patients switch providers.
Ethionamide sits in the family of drugs flagged for significant risk, so facilities lay down strict controls. Drug handling rooms need ventilation, spill kits, and routine staff training. Personnel wear gloves and gowns, and all residues and remains require incineration under licensed protocols. Pharmacies warn users to report signs of hepatitis, neuropathy, or vision changes right away. Routine liver function tests are the rule, not the exception, during therapy. In the clinic, direct observation ensures people take medicines as prescribed, limiting both the rise of resistance and the chance for missed doses. WHO guidelines and local regulations demand detailed record-keeping spanning from storage to administration.
Most doctors reach for ethionamide when facing multidrug-resistant tuberculosis, especially in places like Eastern Europe, South Africa, and Southeast Asia, where MDR-TB rates run high. It forms part of layered treatment regimens, working alongside cycloserine, fluoroquinolones, and injectable antibiotics. Its use stretches into pediatric cases and, with great caution, into pregnant women when no better option presents itself. Outside TB, a few rare stubborn infections receive attention, though success stories remain limited due to the drug’s side effect burden and better options for most bugs. Global supply chains keep stock moving to clinics where the fight remains urgent.
Research on ethionamide pivots on one key question: How can side effects be managed or reduced? Countless trials analyze dosing schedules, seek drug combinations that might soften the gastrointestinal blow, and look at new delivery forms—liposomal, nano-coated, or layered with slow-release carriers. Teams investigate biomarkers to predict who will tolerate treatment well, aiming for a future where care can be personalized. Academic consortia keep searching for fresh derivatives, hoping to unlock molecules with the same bacterial knockout punch but fewer headaches for patients. The quest takes on new urgency as MDR-TB numbers stay stubborn, and global budgets tighten for new antibiotic discovery.
Long-running studies catalog the harm that can follow extended ethionamide therapy. Hepatotoxicity stands as the major fear—patients watch their liver enzymes rise, and doctors wrestle with the risk of ongoing damage. Peripheral neuropathy, often felt as numbness or tingling in the feet and hands, makes walking difficult for some. Mental changes, including confusion or even psychosis, crop up, making drug monitoring more than paperwork—a true lifeline for vulnerable patients. Kids show different risk patterns, sometimes bouncing back, sometimes stuck with lasting sensory changes. Feeding real-world safety data into databases pushes the development of new medication safety practices, especially where infrastructure lags behind.
Ethionamide’s story is far from over. Ongoing antibiotic resistance signals the need for tailored use, not blanket deployment. Some researchers pin their hopes on combination pills, using just enough ethionamide to clear infection while cutting down side effects. Digital health tools may soon track side effects and compliance in real time, flagging up problems before they grow. As researchers continue engineering new analogues, there’s interest in compounds that keep the core but swap out troublesome bits of the molecule. Old drugs often teach new lessons in modern times—a theme familiar to anyone grappling with treatment-resistant infections. If managers coordinate procurement and proper oversight, supply will stay secure in the clinics that need it most.
Ethionamide stands among those medicines that rarely make headlines, but for people dealing with tuberculosis—especially the kind that shrugs off standard treatment—it matters in a big way. This drug helps curb the disease when first-line antibiotics fall short. Multidrug-resistant tuberculosis creates immense challenges for doctors and patients alike, and treatment takes time, money, and tenacity. I’ve seen the toll TB can take on families and communities. A single case can sideline a breadwinner, upend daily routines, and lead to months of worry. Reliable backup options like ethionamide become lifelines when front-runners like isoniazid or rifampicin can’t finish the job.
Tuberculosis ranks as one of the top infectious killers worldwide. The World Health Organization estimates millions of new infections each year, with some strains growing wise to older drugs. Over time, misuse, missed doses, or incomplete courses give bacteria the room they need to develop resistance. Once resistance shows up, doctors need more tools.
Ethionamide operates by blocking certain bacteria enzymes, throwing up a roadblock in the germ’s efforts to keep growing. The goal is simple—starve out the infection. It doesn’t work alone; doctors usually team it with other medicines to close loopholes and push back against the clever mutations of TB bacteria.
Anyone who has lived through the slow drag of tuberculosis—persistent cough, fatigue, weight drop—knows hope comes from knowing there’s still another plan when Plan A lets them down. I’ve spoken with patients who’ve run through the antibiotic list and worried their options had run dry. Ethionamide, though far from perfect, often offers a last shot.
While ethionamide deals a good punch to TB bacteria, it doesn’t do so without side effects. Nausea, upset stomach, even changes in mood or nerves can hit hard. Compliance makes all the difference. Losing faith in the medicine or stopping early just hands the disease another advantage. Good support and education really matter. If a patient understands what’s coming, it’s easier to tough it out, get regular checkups, tweak doses if needed, and finish strong. I remember working in a clinic where we’d spend extra time walking through pill bottles and side effect charts, just to make sure nobody felt left behind or blindsided.
Kids, pregnant women, and people with weak immune systems need special care. The balance between killing bacteria and protecting overall health always stays in sharp focus. Governments and non-profit organizations that focus on TB care often try to make these treatments more accessible, affordable, and less intimidating for patients.
Access to newer, less harsh drugs would make a world of difference. More funding for research could speed up discovery of stronger, safer ways to knock out TB. For now, making sure people know about supporting services, treatment options, and the importance of completing any course goes a long way toward real recovery. Bringing TB into the spotlight, continuing honest conversation around hard-to-treat infections, and leaning on community health workers for follow-up all play big roles.
People affected by tuberculosis deserve better futures. Ethionamide isn’t the end of the road; it’s a reminder of science’s ongoing promise to keep pushing for stronger, smarter answers in global health.
Ethionamide plays a role in fighting tuberculosis, especially for people dealing with a form that no longer responds to regular drugs. This medicine doesn’t come without challenges. Doctors warn their patients, and for good reason. Personal stories echo across clinics and online health forums. People notice their bodies changing after they start taking Ethionamide, often within the first weeks.
Stomach problems lead the pack. People often face nausea, sometimes along with vomiting or a poor appetite. It’s a tough balancing act: stopping the medicine isn’t an option, but forcing food down feels like a challenge. Some days, the smell of a favorite meal turns the stomach. For a handful of people, diarrhea joins the list, adding to the discomfort.
Shifts in mood and thoughts sneak up on folks. It’s not rare to hear about depression or strange dreams after starting Ethionamide. Anxiety sometimes creeps in, and concentration slips away. Families notice changes too—withdrawal from activities, irritability, or even talking about hopelessness. Psychiatric side effects scare many into calling their doctor but with the right support, people push through the fog.
A metallic taste in the mouth sends some searching for mints and other distractions. This taste lingers, often making food less enjoyable. Some lose interest in eating, not because they lack hunger, but because nothing tastes right. Changing toothbrush brands or chewing gum from time to time can offer short-lived relief.
The liver works hard to process tuberculosis drugs, and Ethionamide makes it sweat. Blood tests reveal the strain—elevated liver enzymes pop up, and some doctors catch this early. Jaundice appears as yellowed skin in serious cases but staying ahead with regular lab work helps spot trouble before things escalate. Cutting out alcohol during treatment makes a real difference. Recent papers from clinics in India and South Africa stress the importance of regular blood checks.
The thyroid gland also takes a hit, especially with longer use. Low hormone levels show up as tiredness, weight gain, or feeling unusually cold. Talk to enough people on this medicine, and someone will mention dragging themselves through the day or noticing a slow pulse. For those already battling thyroid issues, a doctor’s close watch and possible adjustments to other medicines turn into part of the routine.
These side effects don’t have to win out. Some tricks add comfort—smaller, more frequent meals and eating bland foods can tame nausea. Friends and family spot mood changes first; talking honestly about those shifts helps. Keeping a diary of symptoms, logging changes in appetite or mood, can flag danger signs early. Open conversation with a health provider makes tweaks possible—adjusting doses or adding supportive medication. What matters most is not hiding new symptoms out of fear or embarrassment.
Ethionamide’s side effects challenge the strongest among us, but knowledge and open discussion build a safer path. Staying vigilant, asking questions, and drawing on the experiences of others bring a sense of control. Medicines take teamwork—between a patient, their family, and clinic staff—so people reach the end of treatment in the best shape possible.
People dealing with tuberculosis often hear about ethionamide. This isn’t a go-to medicine unless the illness puts up a fight against other treatments. When someone’s doctor writes out ethionamide on their slip, it’s not just another tablet to add to the pile; it’s a marker that the infection needs a firmer response. Over the years, my work with TB clinics has given me front-row insight into why doctors keep a close eye on folks using this drug. Side effects pop up more than patients expect, and missing a dose can set someone back weeks.
Swallowing ethionamide whole with water makes a difference, mostly because crushing or splitting can kick up the risk of stomach pain. Some patients swallow the pill with food to spare their stomach, especially since queasiness often joins the show early on. I’ve watched quite a few people give up because the nausea drags them down every day. Doctors usually encourage these patients to take ethionamide with a light meal, maybe some bread or a banana, rather than skipping it altogether or chasing it down with strong coffee.
The medicine works best when it’s taken at the same time each day. Gaps or skipped pills mean infection grows back stronger, and soon, nothing works well. From my time volunteering at community clinics, the message is clear: set a daily alarm, buddy up with a friend who checks in, or log each pill in a notebook. Staying on track builds up the fight against TB faster.
Ethionamide stirs up side effects for many—think bad breath, metal taste, nausea, or throwing up. Sometimes, folks get mood changes or nerve issues, especially those skipping vitamin B6. Doctors almost always add vitamin B6 for this reason. I saw a man’s progress stall out simply because no one explained why he needed the supplement. Once he did, the tingling in his feet faded, and he finished his treatment without quitting.
Regular bloodwork and liver checks aren’t just a formality. Ethionamide can be rough on the liver, and high readings mean it’s time to adjust the dose. I’ve sat with patients who thought blood tests were just for show until sudden fatigue and dark urine showed up. Catching problems early let them get the care they needed before the damage became permanent.
Ethionamide isn’t a solo journey drug—doctors, pharmacists, nutritionists, and in some cases, family or community health workers all play a role. Missing information can trip patients up in unexpected ways. I remember one teenager who mixed up his pills and doubled his dose by accident, too embarrassed to ask for help. As soon as his aunt stepped in and started sorting everything in a weekly pill case, the mix-ups stopped.
Ethionamide can interact with foods, alcohol, and other drugs. Each time someone adds something new—over-the-counter cough drops, herbal teas, or even just a different brand of multivitamin—it’s worth a quick chat with the pharmacy staff. They often catch problems before they start.
Completing the full course means sticking through the tough days as well as the good ones. In my experience, folks do best when they connect their daily routine to the pills—taking them during breakfast or right before an evening TV program. For many, seeing improvement in their health and getting encouragement from the care team or family helps them keep going. Ethionamide isn’t an easy medication, but with the right support and solid habits, people come out the other side healthier and stronger.
Anyone who’s experienced pregnancy—growing a life, seeing ultrasounds, feeling the weight of new responsibility—knows there’s never a simple choice when it comes to medication. Taking any drug during this period stirs up a mix of fear and hope in parents, especially with diseases as serious as tuberculosis. For decades, doctors have worried about ethionamide, a second-line tubercular drug, and the risks that come with its use while pregnant. People want facts, not medical jargon.
Let’s look straight at the heart of the issue. Ethionamide serves as a lifeline for patients with multi-drug resistant tuberculosis (MDR-TB), but it’s far from gentle. Studies in animals have shown that high doses can cause birth defects. Pregnant people have always stood close to the edge, weighing the risk of untreated TB—which itself can lead to death of mother and baby—against the shadowy threat of possible birth defects.
Unlike drugs with clear yes or no answers, ethionamide sits in a gray zone. Pregnancy safety data in humans remains limited because there’s never been a large, controlled trial that tracked babies exposed to this medicine in the womb. Still, scattered case reports and small studies suggest problems like low birth weight, early delivery, and some malformations, but not so commonly that people can pin a direct cause-and-effect.
Doctors who’ve spent careers treating TB in resource-limited settings know these decisions aren't just clinical—there’s real pressure, especially if a mother’s life is at stake. At times, there’s no gentler alternative that fights resistant TB strains as effectively. Ethionamide gets pulled off the shelf, risks and all, because untreated MDR-TB can almost guarantee worse outcomes for mothers and babies.
Treatment guidelines from groups like the World Health Organization don’t give a green light, but they don’t slam the door, either. Instead, they call for case-by-case decision-making, pushing doctors, mothers, and families into heavy conversations. It’s a balance—a parent’s future, a baby’s future, the reality of TB’s danger.
Sitting across from a worried mother, sharing what’s known about ethionamide feels raw. Telling someone about the animal studies; not hiding the uncertainty about human data. Outlining the risks that come with stopping TB treatment. Providing the numbers: global MDR-TB rates rising, maternal and infant deaths climbing in untreated cases. Doctors recommend regular ultrasound scans, close monitoring, and nutritional support if ethionamide becomes necessary. They push for patient counseling, checking and double-checking mental health, and involving family or community support.
People deserve better answers. Clinical researchers can help by tracking outcomes in larger groups of pregnant women exposed to MDR-TB drugs, including ethionamide. Real stories—not just statistics—can shape guidelines and help providers and patients make tough choices. Expanding access to newer, safer anti-TB drugs also has promise, as does strengthening TB prevention to keep mothers healthy in the first place. For now, every decision rests on clear conversations and keeping people at the center of medical care.
Ethionamide has a key place in the fight against tuberculosis, especially drug-resistant cases. It’s a tough medication for a tough infection. But I’ve learned from following patient stories that taking it brings a complicated mix of good and bad. As with most drugs used for complex infections, ethionamide doesn’t work in isolation. It often travels alongside a host of other medications, and that’s where things get tricky.
Doctors know the value of asking about every single pill a patient takes. Anti-tuberculosis antibiotics can tangle with other drugs in ways that could cause problems. Among the most concerning interactions: ethionamide can worsen the nerve damage caused by other TB drugs like isoniazid. In practice, that means doctors may see more patients with numbness and tingling in their hands or feet. This isn’t the kind of side effect anyone wants to ignore, especially if a patient relies on working hands for everyday living.
Another big concern: medications for diabetes. Ethionamide has an impact on blood sugar, sometimes making it drop lower than expected. For someone with diabetes, this can sneak up and cause serious trouble, like confusion, sweating, or even loss of consciousness. Too often, I hear about patients monitoring their blood sugar just to find sudden changes. If you have a family member on insulin or pills for diabetes, and they’re also prescribed ethionamide, it’s worth a conversation to double-check how best to watch for warning signs.
Every doctor treating tuberculosis keeps an eye on thyroid function. Ethionamide can cause trouble for the thyroid, and some other drugs do this too. People might notice unexplained tiredness, weight gain, or mood changes. These can get chalked up to the illness itself, but untreated thyroid issues only add to the burden. Good practice means thyroid levels get checked during treatment, catching problems before symptoms spiral out of control.
Mental health often gets left out in talks about medication interactions, but ethionamide’s side effects can include depression or even psychosis. Adding other medications with similar effects—sometimes antidepressants or seizure drugs—may intensify these problems. Families have shared stories of changes in mood or behavior that take them by surprise, leading to real worry. Keeping communication open, tracking symptoms, and not dismissing mental or emotional shifts can truly help.
No one wants to juggle these risks alone. Regular check-ins help both doctors and patients stay ahead of trouble. A lot goes back to practical support: teaching people the warning signs of side effects, showing them how to track symptoms, and making sure they have a team ready to answer urgent questions. Pharmacists play a big role by double-checking medications for possible cross-reactions before someone leaves the pharmacy.
Getting through TB treatment is hard enough without adding new problems. With medication interactions, small changes in routine can mean the difference between a manageable journey and a crisis. People living with tuberculosis already fight an uphill battle. By looking out for drug interactions, families, patients, and doctors keep each other a little safer, and that’s something worth investing real energy in.
| Names | |
| Preferred IUPAC name | 2-ethylpyridine-4-carbothioamide |
| Other names |
2-ethylpyridine-4-carbothioamide ETH ethionamid ethionamide hydrochloride Trecator Trecator-SC |
| Pronunciation | /ɛˌθaɪˈɒnəˌmaɪd/ |
| Identifiers | |
| CAS Number | 536-33-4 |
| Beilstein Reference | 1361445 |
| ChEBI | CHEBI:4892 |
| ChEMBL | CHEMBL973 |
| ChemSpider | 6158 |
| DrugBank | DB00616 |
| ECHA InfoCard | ECHA InfoCard: 100.007.684 |
| EC Number | 3.5.4.16 |
| Gmelin Reference | 7236 |
| KEGG | C07453 |
| MeSH | D004990 |
| PubChem CID | 3306 |
| RTECS number | RA1400000 |
| UNII | YXW2FZ01KV |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C8H10N2S |
| Molar mass | 166.24 g/mol |
| Appearance | Yellow crystalline powder |
| Odor | Faint odor of sulfur |
| Density | 1.25 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 0.90 |
| Vapor pressure | 2.3 x 10^-7 mmHg (25 °C) |
| Acidity (pKa) | 4.61 |
| Basicity (pKb) | 3.53 |
| Magnetic susceptibility (χ) | -69.0e-6 cm³/mol |
| Refractive index (nD) | 1.668 |
| Dipole moment | 2.71 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 329.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -67.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4087 kJ/mol |
| Pharmacology | |
| ATC code | J04AD03 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes skin and eye irritation, may cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H351, H335 |
| Precautionary statements | Precautionary statements: If medical advice is needed, have product container or label at hand. Keep out of reach of children. Read label before use. |
| NFPA 704 (fire diamond) | 2-3-0 |
| Flash point | 100 °C (212 °F; 373 K) |
| Autoignition temperature | 605 °C |
| Lethal dose or concentration | LD50 (oral, rat): 562 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rat oral 561 mg/kg |
| NIOSH | WN8U8B6K7U |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Ethionamide: "Not established |
| REL (Recommended) | 100 mg |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds |
Prothionamide Isoniazid Pyrazinamide Thioacetazone |
